United States Pharmaceutical Supply Chain Review Act

The United States Pharmaceutical Supply Chain Review Act, introduced in the 118th Congress as S.5206 on September 25, 2024, aims to address issues within the pharmaceutical supply chain. It includes provisions focused on reviewing and potentially restructuring aspects of the supply chain to ensure efficiency and accountability. The bill likely mandates assessments of current practices, identifies areas for improvement, and may propose specific changes or regulations to enhance the transparency and effectiveness of pharmaceutical distribution. For detailed information, the official PDF version of the bill can be accessed at https://www.congress.gov/118/bills/s5206/BILLS-118s5206is.pdf.